Reply to Jakovac and to Rocha et al.: Can vitamin D prevent or manage COVID-19 illness?
2020; American Physiological Society; Volume: 319; Issue: 2 Linguagem: Inglês
10.1152/ajpendo.00348.2020
ISSN1522-1555
AutoresAndrzej Słomiński, Radomir M. Slominski, Paul A. Goepfert, Tae‐Kang Kim, Michael F. Holick, Anton M. Jetten, Chander Raman,
Tópico(s)COVID-19 Clinical Research Studies
ResumoLetter to the EditorReply to Jakovac and to Rocha et al.: Can vitamin D prevent or manage COVID-19 illness?Andrzej T. Slominski, Radomir M. Slominski, Paul A. Goepfert, Tae-Kang Kim, Michael F. Holick, Anton M. Jetten, and Chander RamanAndrzej T. SlominskiDepartment of Dermatology, University of Alabama at Birmingham, Birmingham, AlabamaVeterans Administration Medical Center, Birmingham, Alabama, Radomir M. SlominskiDepartment of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AlabamaDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, Paul A. GoepfertDepartment of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AlabamaDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, Tae-Kang KimDepartment of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, Michael F. HolickDepartment of Medicine, Boston University, Boston, Massachusetts, Anton M. JettenCell Biology Section, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina, and Chander RamanDepartment of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AlabamaDivision of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AlabamaPublished Online:13 Aug 2020https://doi.org/10.1152/ajpendo.00348.2020MoreSectionsPDF (594 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations ShareShare onFacebookTwitterLinkedInWeChat to the editor: The outstanding articles by Jakovac (4) and Rocha et al. (8) emphasize an association between vitamin D deficiency/insufficiency and enhanced coronavirus disease (COVID-19) severity, which is also presented in recent reports (1, 3), and led to unofficial recommendations for taking vitamin D supplements (https://doi.org/10.1016/S2213-8587(20)30183-2). Therefore, we want to further discuss this issue on different levels.COVID-19 pandemic.As the COVID-19 pandemic accelerates, it is important to explore different therapeutic options that are effective, economical, and without significant side effects. The clinical spectrum of COVID-19 presentation is wide, ranging from asymptomatic infection to severe viral pneumonia associated with respiratory failure from acute respiratory distress syndrome (ARDS) and multi-organ failure. Older people, racial minorities, and patients with a variety of comorbidities are at higher risk of being vitamin D deficient. The same populations are affected disproportionally by severe symptoms and increased mortality from the COVID-19.Cytokine storm and oxidative stress take the center stage at the COVID-19 pathophysiology.Around 5% of patients develop ARDS from a likely dysfunctional immune response, which results in a cascade of events leading to a "cytokine storm". The main proinflammatory elements in a cytokine storm are IL-1β, IL-6, TNFα, INFγ, and IL-17 (7). In severe cases, these inflammatory responses lead to the damage to the lung and other organs, culminating in the end-stage disease (7). The important master regulator of proinflammatory responses is NF-κΒ, while Th17 responses are downstream of retinoic acid receptor-related orphan (RORγ) (5). Oxidative stress can be another etiological factor in the development of ARDS. It can be triggered by viruses and it can activate toll-like receptors (TLR) with subsequent release of cytokines (6). Nuclear factor erythroid 2p45-related factor 2 (NRF-2) plays an important role in the induction of antioxidative responses (6). The oxidative stress induced by the viral infection or cytokine storm can act reciprocally in a vicious cycle to amplify the damage inflicted on the target organs. Therefore, placing the break on this vicious, self-amplifying cycle without toxic side effects and an impairment of the anti-viral host response, would represent a logical management of COVID-19 (Fig. 1).Fig. 1.Active forms of vitamin D3 by counteracting cytokine storm and oxidative stress will attenuate acute respiratory distress syndrome (ARDS) secondary to coronavirus disease. Arabic numbers, positions of hydroxyl groups on vitamin D3; n, number of hydroxyl groups; CYP11A1, CYP2R1, and CYP27B1, enzymes hydroxylating vitamin D3 with CYP2R1 hydroxylating at C25 and CYP 27B1 hydroxylating 25(OH)D3 at C1α to generate 1,25(OH)2D3 (calcitriol); SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.Download figureDownload PowerPointVitamin D solution.Active forms of vitamin D, including the classical calcitriol [1,25(OH)2D3] (2), and novel CYP11A1-derived hydroxyderivatives can inhibit production of proinflammatory cytokines of a cytokine storm with a mechanism of action involving downregulation of NF-κΒ and inverse agonism on RORγ (10). They can also counteract the oxidative stress through activation of NRF-2 and p53-dependent pathways (10). Therefore, we suggest that vitamin D3-hydroxyderivatives are candidates for management of COVID-19, because while targeting both the cytokine storm and oxidative stress, they might also have antiviral effects (Fig. 1). However, their immediate clinical use has limitations, because it requires FDA approval for CYP11A1-derived hydroxyderivatives or for administration of calcitriol, 25-hydroxyvitamin D or 1α-hydroxyvitamin D for severe symptoms of COVID-19 (2). Vitamin D precursor, however, is readily available and can be consumed within reasonable doses without a need for such approval. According to the Endocrine Society, the upper daily limit for an average healthy adult individual is 10,000 IU/day. This oral dose could be applied preventively to reduce probability of moderate to severe COVID-19. However, such a dose may not be sufficient to stop cytokine↔oxidative storm in patients entering the hospital, which would require aggressive solutions. In the past, mega doses of vitamin D were used to treat different pathologies (2). In most recent studies, 200,000 IU, but not 50,000 IU, of orally delivered vitamin D3 was effective in significant attenuation of proinflammatory responses induced by solar radiation after 48 h of observation without any sign of toxicity (9). These findings suggest the use of high doses of vitamin D after admission to the hospital, since patients can be carefully monitored for any signs of adverse effects.Considering the routes and forms of delivery, in the United States, only oral forms are available in the form of pills or liquid. Intravenous delivery at high doses is not available, and vitamin D3 form for intramuscular injections is marketed in Europe and India.We agree with Jakovac (4) and Rocha et al. (8) that this calls for measurement of a 25(OH)D level in all COVID-19 patients. Patients who are vitamin D deficient or insufficient, i.e., 25(OH)D < 30 ng/mL could be treated with an appropriate amount of vitamin D as soon as it is feasible to do so. In summary, we believe that different forms and routes of delivery of vitamin D at proper and clinically monitored doses might help in prevention or management of moderate to severe COVID-19.GRANTSThis work was supported in part by the NIH grants 1R01AR073004 and R01AR071189 and VA merit 1I01BX004293-01A1 to A.T.S.DISCLOSURESMichael F. Holick is on the Speakers Bureau for Abbott, former consultant for Quest diagnostics, and a consultant Ontometrics Inc. None of the other authors has any conflicts of interest, financial or otherwise, to disclose.AUTHOR CONTRIBUTIONSA.T.S. and T.-K.K. prepared figures; A.T.S., R.M.S., P.A.G., M.F.H., A.M.J., and C.R. drafted manuscript; A.T.S., R.M.S., P.A.G., M.F.H., A.M.J., and C.R. edited and revised manuscript; A.T.S., R.M.S., P.A.G., T.-K.K., M.F.H., A.M.J., and C.R. approved final version of manuscript.REFERENCES1. D'Avolio A, Avataneo V, Manca A, Cusato J, De Nicolò A, Lucchini R, Keller F, Cantù M. 25-Hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2. Nutrients 12: 12, 2020. doi:10.3390/nu12051359. Crossref | PubMed | ISI | Google Scholar2. Holick MF. Vitamin D deficiency. N Engl J Med 357: 266–281, 2007. doi:10.1056/NEJMra070553. Crossref | PubMed | ISI | Google Scholar3. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res 32: 1195–1198, 2020. doi:10.1007/s40520-020-01570-8. Crossref | PubMed | ISI | Google Scholar4. Jakovac H. COVID-19 and vitamin D-Is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab 318: E589, 2020. doi:10.1152/ajpendo.00138.2020. Link | ISI | Google Scholar5. Jetten AM, Cook DN. (Inverse) agonists of retinoic acid-related orphan receptor γ: regulation of immune responses, inflammation, and autoimmune disease. Annu Rev Pharmacol Toxicol 60: 371–390, 2020. doi:10.1146/annurev-pharmtox-010919-023711. Crossref | PubMed | ISI | Google Scholar6. Lee C. Therapeutic modulation of virus-induced oxidative stress via the nrf2-dependent antioxidative pathway. Oxid Med Cell Longev 2018: 6208067, 2018. doi:10.1155/2018/6208067. Crossref | PubMed | ISI | Google Scholar7. Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol 20: 345–346, 2020. doi:10.1038/s41577-020-0328-z. Crossref | PubMed | ISI | Google Scholar8. Rocha JC, Calhau C, MacDonald A. Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective? Am J Physiol Endocrinol Metab 318: E890–E891, 2020. doi:10.1152/ajpendo.00195.2020. Link | ISI | Google Scholar9. Scott JF, Das LM, Ahsanuddin S, Qiu Y, Binko AM, Traylor ZP, Debanne SM, Cooper KD, Boxer R, Lu KQ. Oral vitamin D rapidly attenuates inflammation from sunburn: an interventional study. J Invest Dermatol 137: 2078–2086, 2017. doi:10.1016/j.jid.2017.04.040. Crossref | PubMed | ISI | Google Scholar10. Slominski AT, Chaiprasongsuk A, Janjetovic Z, Kim TK, Stefan J, Slominski RM, Hanumanthu VS, Raman C, Qayyum S, Song Y, Song Y, Panich U, Crossman DK, Athar M, Holick MF, Jetten AM, Zmijewski MA, Zmijewski J, Tuckey RC. Photoprotective properties of vitamin D and lumisterol hydroxyderivatives. Cell Biochem Biophys 78: 165–180, 2020. doi:10.1007/s12013-020-00913-6. Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESCorrespondence: A.T. Slominski (aslominski@uabmc.edu);C. Raman (chanderraman@uabmc.edu). Download PDF Previous Back to Top Next FiguresReferencesRelatedInformation CollectionsAPS Cross-Journal CollectionsCoronavirus-Related Papers Related ArticlesCOVID-19 and vitamin D—Is there a link and an opportunity for intervention? 16 Apr 2020American Journal of Physiology-Endocrinology and MetabolismReply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective? 01 Jun 2020American Journal of Physiology-Endocrinology and MetabolismCited ByVitamin D3 and its hydroxyderivatives as promising drugs against COVID-19: a computational study20 August 2021 | Journal of Biomolecular Structure and Dynamics, Vol. 40, No. 22Novel CYP11A1-Derived Vitamin D and Lumisterol Biometabolites for the Management of COVID-1911 November 2022 | Nutrients, Vol. 14, No. 22Vitamin D as the essential immunonutrient – the evidence base update: A review30 July 2022 | Pediatrics. Consilium Medicum, No. 2Vitamin D and COVID-19. Two years of researchRussian Pediatric Journal, Vol. 25, No. 3Serum levels of vitamin D and immune system function in patients with COVID-19 admitted to intensive care unitGene Reports, Vol. 26Phytomelatonin: a potential phytotherapeutic intervention on COVID-19-exposed individualsMicrobes and Infection, Vol. 24, No. 1The coronavirus disease (COVID-19) – A supportive approach with selected micronutrientsInternational Journal for Vitamin and Nutrition Research, Vol. 92, No. 1Vitamin D and COVID-19: where are we now?27 December 2021 | Postgraduate Medicine, Vol. 14Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits1 April 2021 | Expert Review of Anti-infective Therapy, Vol. 19, No. 10Vitamin D and COVID-19: An Overview of Recent Evidence29 September 2021 | International Journal of Molecular Sciences, Vol. 22, No. 19Relevance of vitamin D3 in COVID-19 infectionGene Reports, Vol. 24Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications29 April 2021 | Nutrients, Vol. 13, No. 5Vitamin D and SARS-CoV-2 Infection24 March 2021 | Asian Journal of Organic & Medicinal Chemistry, Vol. 6, No. 1Association Between Vitamin D and Novel SARS-CoV-2 Respiratory Dysfunction – A Scoping Review of Current Evidence and Its Implication for COVID-19 Pandemic26 November 2020 | Frontiers in Physiology, Vol. 11Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin DInternational Immunopharmacology, Vol. 88 More from this issue > Volume 319Issue 2August 2020Pages E455-E457 https://doi.org/10.1152/ajpendo.00348.2020PubMed32787704History Received 6 July 2020 Accepted 6 July 2020 Published online 13 August 2020 Published in print 1 August 2020 Metrics
Referência(s)